1-800-887-8100
COPAXONE® (glatiramer acetate injection) 40 mg/mL Logo
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
MENU
Shared Solutions®
DOWNLOAD PRESCRIPTION & SERVICE REQUEST FORM (PSR)
Copaxone® is the #1 prescribed brand for relapsing MS in the US 1*

Trust in a demonstrated safety and tolerability profile1

The tolerability of COPAXONE® may allow patients to stay on therapy so they can experience the potential clinical benefits.

Pregnancy

Pregnancy Category B1

Animal studies have failed to demonstrate a risk to the fetus. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, COPAXONE® should be used in pregnancy only if clearly needed.1

Tolerability

In the 3-times-a-week COPAXONE® 40 mg/mL clinical trial1

  • 91% of patients treated with COPAXONE® 40 mg/mL stayed on therapy for over 12 months

  • Approximately 3% of patients treated with COPAXONE® 40 mg/mL discontinued treatment due to an AE

Drug Interactions

Interactions between COPAXONE® and other drugs have not been fully evaluated. Results from existing clinical trials do not suggest any significant interactions of COPAXONE® with therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days. COPAXONE® has not been formally evaluated in combination with interferon beta.1

Fewer Injections

3-times-a-week COPAXONE® 40 mg/mL offers your patients 208 fewer injections per year compared with daily COPAXONE® 20 mg/mL.1

Explore the efficacy data of 3-times-a-week COPAXONE® 40 mg/mL

3-times-a-week COPAXONE® 40 mg/mL AE rates

In a controlled study of COPAXONE® 40 mg per mL, the most common adverse reactions with COPAXONE® vs placebo were ISRs, such as erythema (22% vs 2%).1

Most common AEs (≥2% and more frequent with 3-times-a-week COPAXONE® 40 mg/mL vs placebo)1

Event
COPAXONE® 40 mg/mL
(n=943)
Placebo
(n=461)
General disorders and injection site conditions:
Injection site erythema
22%
2%
Injection site pain
10%
2%
Injection site mass
6%
0%
Injection site pruritus
6%
0%
Injection site edema
6%
0%
Pyrexia
3%
2%
Influenza-like illness
3%
2%
Injection site inflammation
2%
0%
Chills
2%
0%
Chest pain
2%
1%
Infections and infestations
Nasopharyngitis
11%
9%
Respiratory tract infection viral
3%
2%
Dyspnea
3%
0%
Vasodilatation
3%
0%
Nausea
2%
1%
Erythema
2%
0%
Rash
2%
1%

With 3-times-a-week COPAXONE® 40 mg/mL, your patients can experience fewer injections1*

Injections per year

365
156
208fewer
injections
per year*
*Compared with daily COPAXONE® 20 mg/mL

See how 3-times-a-week COPAXONE® 40 mg/mL was proven effective in the largest COPAXONE® clinical trial to date.

SEE STUDY RESULTS
A proven mix of efficacy, safety, and tolerability in relapsing forms of MS
SEE STUDY RESULTS
Discover how COPAXONE® is thought to work
Learn more
Teva’s Shared Solutions® offers a full range of support services to help your COPAXONE® patients reach their treatment goals
See All Services

Reference

  1. COPAXONE® (glatiramer acetate injection) prescribing information. Rev. 8/2016. Teva Neuroscience, Inc.

Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.

IMPORTANT SAFETY INFORMATION

COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of

You are now leaving this website

The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.

While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.

Continue to site
×